News
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...
Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...
Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...
14h
Clinical Trials Arena on MSNVertex presents data from Phase I/II stage of trial for type 1 diabetesThe safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results